Valproic acid and all-trans retinoic acid: Meta-analysis of a palliative treatment regimen in AML and MDS patients

Onkologie

Volumn 31, Issue 11, 2008, Pages 629-633

  Bellos, Frauke ^a   Mahlknecht, Ulrich ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Acute myeloid leukemia; All trans retinoic acid; HDAC inhibitors; Myelodysplastic syndrome; Valproic acid

Indexed keywords

LACTATE DEHYDROGENASE; RETINOIC ACID; VALPROIC ACID;

ABDOMINAL CRAMP; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; CANCER PALLIATIVE THERAPY; CELL COUNT; CHEILITIS; CLINICAL ARTICLE; DRUG ERUPTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FATIGUE; FEVER; GERIATRIC PATIENT; HUMAN; HYPERKERATOSIS; LACTATE DEHYDROGENASE BLOOD LEVEL; MAINTENANCE THERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; RETINOIC ACID SYNDROME; RETROSPECTIVE STUDY; REVIEW; STOMATITIS; THROMBOCYTE TRANSFUSION; TINNITUS; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PALLIATIVE CARE; PREVALENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRETINOIN; VALPROIC ACID;

EID: 58849158362     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000160599     Document Type: Review

References (23)

1. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman PP, Lee EJ, Moore JO, Powell BL, Baer MR, Bloomfield CD, Schiffer CA: Postremission therapy in older patients with de novo acute myeloid leukemia: A randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 2001;98:548-553.
2. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001;20:6969-6978.
3. Werling U, Siehler S, Litfin M, Nau H, Gottlicher M: Induction of differentiation in F9 cells and activation of peroxisome proliferator-activated receptor delta by valproic acid and its teratogenic derivatives. Mol Pharmacol 2001;59:1269-1276.
4. Kawagoe R, Kawagoe H, Sano K: Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways. Leuk Res 2002;26:495-502.
5. Bug G, Schwarz K, Schoch C, Kampfmann M, Henschler R, Hoelzer D, Ottmann OG, Ruthardt M: Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia. Haematologica 2007;92:542-545.
6. Kuendgen A, Knipp S, Fox F, Strupp C, Hildebrandt B, Steidl C, Germing U, Haas R, Gattermann N: Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann Hematol 2005;84(suppl 13):61-66.
7. Kuendgen A, Schmid M, Schlenk R, Knipp S, Hildebrandt B, Steidl C, Germing U, Haas R, Dohner H, Gattermann N: The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006;106:112-119.
8. Pilatrino C, Cilloni D, Messa E, Morotti A, Giugliano E, Pautasso M, Familiari U, Cappia S, Pelicci PG, Lo Coco F, Saglio G, Guerrasio A: Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. Cancer 2005;104:101-109.
9. Raffoux E, Chaibi P, Dombret H, Degos L: Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia. Haematologica 2005;90:986-988.
10. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Lowenberg B, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Gore S, Greenberg PL: Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96:3671-3674.
11. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Lowenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD: Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003;21:4642-4649.
12. Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda WG, Ouzounian S, Quezada A, Pierce S, Estey EH, Issa JP, Kantarjian HM, Garcia-Manero G: Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007;110:2302-2308.
13. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'Brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa JP: Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 2006;108:3271-3279.
14. Bug G, Gul H, Schwarz K, Pfeifer H, Kampfmann M, Zheng X, Beissert T, Boehrer S, Hoelzer D, Ottmann OG, Ruthardt M: Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. Cancer Res 2005;65:2537-2541.
15. Kuendgen A, Strupp C, Aivado M, Bernhardt A, Hildebrandt B, Haas R, Germing U, Gattermann N: Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004;104:1266-1269.
16. Siitonen T, Timonen T, Juvonen E, Terava V, Kutila A, Honkanen T, Mikkola M, Hallman H, Kauppila M, Nylanden P, Poikonen E, Rauhala A, Sinisalo M, Suominen M, Savolainen ER, Koistinen P: Valproic acid combined with 13-cis retinoic acid and 1.25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes. Haematologica 2007;92:1119-1122.
17. Schlenk RF, Bommer M, Schmid M, Fröhling S, Lehmann K, Groner S, Hann R, Krauter J, Döhner K, Ganser A, Göttlicher M, Döhner H: Valproic acid as adjunct to induction therapy in patients with acute myeloid leukaemia: First results of two randomized studies of the AMLSG. Blood 2005;106:abstr 2800.
18. Schlenk RF, Frohling S, Hartmann F, Fischer JT, Glasmacher A, del Valle F, Grimminger W, Gotze K, Waterhouse C, Schoch R, Pralle H, Mergenthaler HG, Hensel M, Koller E, Kirchen H, Preiss J, Salwender H, Biedermann HG, Kremers S, Griesinger F, Benner A, Addamo B, Dohner K, Haas R, Dohner H: Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia 2004;18:1798-1803.
19. Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M, Grever M, Galm O, Dauses T, Karp JE, Rudek MA, Zhao M, Smith BD, Manning J, Jiemjit A, Dover G, Mays A, Zwiebel J, Murgo A, Weng LJ, Herman JG: Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006;66:6361-6369.
20. ten Cate B, Samplonius DF, Bijma T, de Leij LF, Helfrich W, Bremer E: The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells. Leukemia 2007;21:248-252.
21. Cimino G, Lo-Coco F, Fenu S, Travaglini L, Finolezzi E, Mancini M, Nanni M, Careddu A, Fazi F, Padula F, Fiorini R, Aloe Spiriti MA, Petti MC, Venditti A, Amadori S, Mandelli F, Pelicci PG, Nervi C: Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Res 2006;66:8903-8911.
22. Nervi C, Lo Coco F, Minucci S, Careddu A, Fiorini R, Finolezzi E, Noguera N, Travaglini L, Gelmetti V, Diverio D, Fenu S, Mancini M, Tatarelli C, Aloe Spitri MA, Petti MC, Cimino G, Mandelli F, Amadori S, Pelicci PG: Valproic acid plus retinoic acid induce myeloid differentiation in chemotherapy-resistant acute myeloid leukaemia patients. Blood 2004;104:abstr 1805.
23. Craddock C, Bradbury C, Narayanan S, Rye A, Basu S, MacWhannell A, Sawers A, Cook M, Griffiths M, Grimwade D, Bunce C, Turner B: Predictors of clinical response in patients with high risk acute myeloid leukaemia receiving treatment with the histone deacetylase inhibitor sodium valproate. Blood 2005;10:abstr 2791.